Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Our AI scores Grail, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Grail, Inc. is a mid-cap company with a market capitalization of $5.42B. It ranks number 7 by market capitalization among the 27 Services-Medical Laboratories issuers in our coverage with a current forecast.
For GRAL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -41.0%, measured on 253 forecast dates between 2024-08-16 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -23.0%, measured on 296 forecast dates between 2024-08-16 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, GRAL included.
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Services-Medical Laboratories peers listed below that report each metric.
| Metric | GRAL | Rank |
|---|---|---|
| Market Cap | $5.42B | 7/27 |
| P/B Ratio | 2.21x | 12/21 |
| EPS | $-9.44 | – |
| Book Value/Share | $54.93 | – |
| Revenue/Share | $3.73 | – |
| FCF/Share | $-6.99 | – |
| Metric | GRAL | Rank |
|---|---|---|
| ROE | -16.6% | 9/13 |
| ROA | -14.9% | 10/18 |
| ROIC | -21.9% | 14/22 |
| Operating Margin | -347.3% | 18/21 |
| Net Margin | -243.8% | 14/16 |
| EBT Margin | -329.0% | 18/21 |
| Tax Rate | 25.9% | – |
| Metric | GRAL | Rank |
|---|---|---|
| Current Ratio | 8.93x | 4/24 |
| D/E Ratio | 0.11x | 17/21 |
| Financial Leverage | 1.11x | 17/21 |
| Working Capital | $748M | 6/24 |
| Metric | GRAL | Rank |
|---|---|---|
| Operating Cash Flow | -$306M | 25/25 |
| Free Cash Flow | -$312M | 17/17 |
| Capital Spending | -$6M | 6/17 |
| FCF/Sales | -187.3% | 15/16 |
| CapEx/Sales | 3.5% | 11/16 |
| Metric | GRAL | Rank |
|---|---|---|
| Asset Turnover | 0.06x | 15/18 |
| Receivables Turnover | 8.8x | 7/19 |
| Fixed Assets Turnover | 3.9x | 11/17 |
| Days Sales Outstanding | 42 days | 13/19 |
| Metric | GRAL | Rank |
|---|---|---|
| Total Revenue | $167M | 12/19 |
| Operating Income | -$579M | 24/24 |
| Net Income | -$406M | 18/19 |
| R&D Expense | $186M | 3/18 |
| SG&A Expense | $435M | 6/19 |
| Metric | GRAL | Rank |
|---|---|---|
| Shares Outstanding | 45M | – |
| Total Current Assets | $843M | 30.9% of assets |
| Cash & Short-term Investments | $29M | 1.1% of assets |
| Accounts Receivable | $19M | 0.7% of assets |
| Total Liabilities | $277M | 10.1% of assets |
| Short-term Debt | $84M | 3.1% of assets |
Companies classified under the same SEC industry code as Grail, Inc. (Services-Medical Laboratories): 28 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| GRAL Grail, Inc. | $5.42B | |
| NTRA Natera, Inc. | $44.78B | |
| LH Labcorp Holdings Inc. | $29.77B | |
| DGX Quest Diagnostics Inc | $28.12B | |
| GH Guardant Health, Inc. | $20.25B | |
| CAI Caris Life Sciences, Inc. | $7.13B | |
| RDNT Radnet, Inc. | $5.98B | |
| BLLN Billiontoone, Inc. | $5.38B | |
| CDNA Caredx, Inc. | $4.13B | |
| CELC Celcuity Inc. | $3.27B | |
| FTRE Fortrea Holdings Inc. | $2.12B | |
| VCYT Veracyte, Inc. | $1.94B | |
| PSNL Personalis, Inc. | $1.69B | |
| LMRI Lumexa Imaging Holdings, Inc. | $1.27B | |
| FRNM Freenome, Inc. | $1.12B | |
| CSTL Castle Biosciences Inc | $993M | |
| FLGT Fulgent Genetics, Inc. | $513M | |
| XGN Exagen Inc. | $184M | |
| BNR Burning Rock Biotech Ltd | $143M | |
| BDSX Biodesix Inc | $90M | |
| SERA Sera Prognostics, Inc. | $82M | |
| MDXH Mdxhealth Sa | $14M | |
| AMS American Shared Hospital Services | $8M | |
| ACON Aclarion, Inc. | $4M | |
| ADVB Advanced Biomed Inc. | $3M | |
| BGLC Bionexus Gene Lab Corp | $3M | |
| FCHS First Choice Healthcare Solutions, Inc. | $150K | |
| RNLXY Renalytix Plc | N/A |
Mott Capital Management, an investment research and management firm, released its “Thematic Growth Strategy” Q3 2026 investor letter. A copy of the letter can be downloaded here. The strategy ...
GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported ...
GRAL is cutting Galleri prices to boost adoption ahead of an expected early 2027 FDA decision, even as pricing pressure weighs on revenue growth and margins.
Our AI scores Grail, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
For GRAL, the Spearman rank correlation between our 90-day forecasts and the returns that followed is -41.0%, measured on 253 forecast dates between 2024-08-16 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -23.0%, measured on 296 forecast dates between 2024-08-16 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Grail, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
28 issuers in our coverage, GRAL included, share the SEC industry code Services-Medical Laboratories. The largest are: Natera, Inc. (NTRA), Labcorp Holdings Inc. (LH), Quest Diagnostics Inc (DGX), Guardant Health, Inc. (GH), Caris Life Sciences, Inc. (CAI), Radnet, Inc. (RDNT).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.
